Cipla appoints Punita Lal and Dr Nachiket Mor as Independent Directors on its Board
Lal will focus on advisory roles and Mor will concentrate in areas of financial access and healthcare
Author
Sultan-ul-Uloom College of Pharmacy celebrates National Education Day
Sultan-ul-Uloom College of Pharmacy in Hyderabad recently celebrated the National Education Day, as a mark of respect to the Birth…
Glenmark enrols first patient for phase II trial of GBR 500
The company out licensed Vatelizumab (GBR 500) to Sanofi for all indications in 2011
US FDA votes against Novartis’ LBH589 compound
(ODAC) did not recommend the investigational compound LBH589, a pan-deacetylase inhibitor, for patients with previously treated…
Study confirms positive safety profile and effectiveness of Pradaxa in atrial fibrillation patients
The FDA Medicare analysis is based on patient data from elderly patients enrolled in Medicare
Clinical Research
What does the next 20 years hold for clinical research in India? Express Pharma presents some perspectives and sugestions for…
Clinical research in India: Where do we go from here?
A policy promoting clinical research and innovation needs to be supported by action at various levels opines Suneela Thatte,…
Bring research back on the agenda
The country has a responsibility towards the health of its citizens that translates to creating an enabling environment, advocates…
CT regulation in India: Science or social justice?
Mark Barnes, JD, LLM Faculty Co-Director, Multi-Regional Clinical Trials Center at Harvard (Harvard MRCT), Lecturer, Harvard Law…
MSF urges India to stand strong against attack on affordable medicines
Many governments and treatment providers rely on affordable quality generic medicines from India to treat life-threatening…